- /
- Supported exchanges
- / US
- / XTLB.NASDAQ
XTL Biopharmaceuticals Ltd ADR (XTLB NASDAQ) stock market data APIs
XTL Biopharmaceuticals Ltd ADR Financial Data Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get XTL Biopharmaceuticals Ltd ADR data using free add-ons & libraries
Get XTL Biopharmaceuticals Ltd ADR Fundamental Data
XTL Biopharmaceuticals Ltd ADR Fundamental data includes:
- Net Revenue: 968 K
- EBITDA: -1 973 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get XTL Biopharmaceuticals Ltd ADR Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2025-12-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XTL Biopharmaceuticals Ltd ADR News
New
XTL BioPharma Closes Acquisition Of Psyga Bio; Shifts Focus To Psychedelic Therapies
(RTTNews) - XTL Biopharmaceuticals Ltd. (XTLB) announced the completion of the acquisition of Psyga Bio Ltd. With the transaction's closure, psychedelic operations will become XTL's exclusive core bus...
XTL Completed the Acquisition of Psyga Bio Ltd.
expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a histor...
XTL Announces Receipt of Staff Delist Determination from Nasdaq
XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has ...
XTL Biopharmaceuticals announces 1-for-4 ADS ratio change
* XTL Biopharmaceuticals (XTLB [https://seekingalpha.com/symbol/XTLB]) will change its ADS ratio [https://seekingalpha.com/pr/20446334-xtl-biopharmaceuticals-announces-ads-ratio-change] from 1:100 ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.